Osteoarthritis of knee joint
Conditions
Interventions
Experimental group :Oral administration of Erichoxib (100mg per dose, twice a day) 1 day before surgery, followed by 100mg of Erichoxib 2 hours after surgery, then 100mg of Erichoxib every 12 hours.
Control group:Oral placebo (100mg per dose, 2 doses per day) 1 day before surgery, followed by 100mg of Eribulin 2 hours after surgery, and then 100mg of Eribulin every 12 hours.
Sponsors
Xi'an Honghui hospital
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. According to the surgical indications, the diagnosis result of knee osteoarthritis by clinical and imaging examination is knee osteoarthritis; 2. The subjects of the study were adult patients who planned to undergo primary unilateral total knee arthroplasty; 3. The age is 50-80 years old; 4. The American Society of Anesthesiology (ASA) evaluates the grade as 1-2; 5. No contraindications; 6. The patient agrees to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Bilateral knee joint replacement, or unilateral hip-knee replacement, or other surgical procedures during the perioperative period; 2. A history of major stress events such as significant trauma, illness, surgery, or family changes within one month before surgery; 3. Significant diseases such as cancer or infections, or other conditions that impact the results of the study; 4. A history of dependence on anesthetic drugs or drug addiction; 5. Difficulty in collecting medical history due to communication barriers or speech impairments that hinder cooperation in related data collection; 6. Patients known to be allergic to etoricoxib or other coxib-type drugs and sulfonamides, those who have induced asthma, urticaria, allergic reactions, gastrointestinal bleeding or perforation history after taking other non-steroidal anti-inflammatory drugs, patients with active peptic ulcers or bleeding, and those with severe heart failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual analog scoring;Knee joint function score;Range of motion of the knee joint;Patient satisfaction score;Blood-related indicators; | — |
Secondary
| Measure | Time frame |
|---|---|
| Consumption of the opioids; | — |
Countries
China
Contacts
Public ContactHuangYuanchi
Xi'an Honghui hospital
Outcome results
None listed